Introduction
Discovery of many tumor suppressor genes (TSGs) has been facilitated by the identi®cation of either homozygous chromosomal deletions or hemizygosity at a particular locus, with functionally inactivating point mutations in the remaining allele. It is now recognized that alternative pathways, such as hypermethylation of CpG islands and other epigenetic mechanisms can also silence tumor suppressor genes in the process of carcinogenesis (Sager, 1997; Baylin et al., 1998) . Nevertheless, functionally inactivating point mutations are generally viewed as the critical`smoking gun' when de®ning a novel TSG.
We recently mapped the HYAL1 gene to human chromosome 3p21.3 (CsoÂ ka et al., 1998) , con®rming its identity with LUCA-1, a candidate tumor suppressor gene frequently deleted in small cell lung carcinomas (SCLC) (Wei et al., 1996) . The HYAL1 gene resides within a commonly deleted region of 3p21.3 where a potentially informative 30 kb homozygous deletion has been found in one SCLC line (Latif et al., 1997) . The position of HYAL1 within this 30 kb homozygous deletion and the larger overlapping homozygous deletions in the NCI H740 and GLC20 SCLC lines leaves this gene a strong candidate TSG. A recent study identi®ed a 220 kb homozygous deletion on 3p21.3 in a breast carcinoma line (Sekido et al., 1998) . The telomeric breakpoint resides approximately 4 kb centromeric to the HYAL1 open reading frame, and overlaps with the centromeric region of the SCLC deletions. In addition to the chromosomal aberrations, the region encompassing 3p21.3 has functional tumor suppressor activity in vivo as determined by monochromosome mediated transfer in a nasopharyngeal carcinoma line (Cheng et al., 1998) . Despite the frequency of homozygous deletions on 3p21.3 in various carcinomas, no mutations have been reported with high frequency in any of the candidate genes examined to date. Hemizygosity over the candidate TSG locus on 3p21.3 has also been reported in head and neck squamous cell carcinomas (HNSCCs) (Buchhagen et al., 1996) . As normal human keratinocytes (NHK) produce Hyal-1 hyaluronidase, the analysis of the status of HYAL1 and the Hyal-1 protein as well as its enzymatic activity in head and neck malignancies appeared to be a rational approach to characterize further this candidate TSG on 3p21.3.
Mammalian hyaluronidases are a family of b, 1 ± 4 endoglucosaminidases that degrade hyaluronan (HA, hyaluronic acid) and to a lesser extent, chondroitin sulfate (Kreil, 1995; Frost et al., 1996; CsoÂ ka et al., 1997a) . Until recently, mammalian hyaluronidases were uncharacterized enzymatic activities present in many tissues, distinguished only on the basis of their pH optima. In the human, it is now established that at least six hyaluronidase-like sequences occur in the human genome, three each at two chromosomal locations: HYAL1, HYAL2, and HYAL3 at chromosome 3p21 (Lepperdinger et al., 1998 ; CsoÂ ka et al., 1999); and HYAL4, SPAM1, and HYALP1 at chromosome 7q31 (CsoÂ ka et al., 1999) . The gene for Hyal-2, HYAL2, a recently identi®ed lysosomal hyaluronidase (Lepperdinger et al., 1998) resides immediately centromeric to HYAL1 on 3p21.3. Hyal-2 possesses an apparent speci®city for high molecular weight HA (420 kDa) and is expressed in all tissues except the brain. PH-20, a GPI anchored hyaluronidase with expression restricted normally to testes, is coded for by SPAM1 on chromosome 7q31 (Gmachl et al., 1993) ¯anked by the two other hyaluronidase-like sequences. Mgea-5 is a seventh hyaluronidase-like protein structurally unrelated to the chromosome 3 and 7 family, coded for by MGEA5 on chromosome 10q, that was identi®ed as a novel immunogenic antigen expressed in meningiomas (Heckel et al., 1998) .
Hyal-1 is a secreted somatic tissue hyaluronidase, and the predominant hyaluronidase in human plasma . Transcripts for Hyal-1 are found in most tissues. Paradoxically, although Hyal-1 is predominantly secreted, it has an acid pH optimum in vitro. HYAL1, identical to LUCA-1, was considered a candidate tumor suppressor gene in SCLC based upon homozygous deletion studies (Wei et al., 1996) . The present study was designed to examine whether Hyal-1 activity is found in cell lines containing the chromosomal aberrations on 3p21.3 characteristic of HNSCC.
Results
Hyal-1 enzyme activity and protein are absent in most cultured HNSCC cell lines Levels of Hyal-1 activity were examined in a panel of seven HNSCC lines derived from primary tumors (SCC-9, SCC-10a, SCC-15, SCC-25) and lymph node metastases (SCC-10b, HOC-313, HSC-3), and compared with the activity of normal human foreskin keratinocytes (NHK) in primary culture. Hyal-1 enzyme activity was measured in immunoprecipitates utilizing the 17E9 anti-Hyal-1 monoclonal antibody in two ways: by HA substrate-gel zymography; and by a microtiter-based assay using biotinylated HA. The substrate-gel zymography of the immunoprecipitates from the squamous cell carcinoma cell lines, cultured serum-free, revealed that only one laryngeal carcinoma line, SCC-10a, expressed hyaluronidase levels comparable to the normal keratinocyte controls (Figure 1) . Cultures of adult oral human keratinocytes (kindly supplied by Dr Ken Zhang, UCSF) were found to synthesize equivalent levels of HYAL1 activity compared to the NHKs (not shown). All other cell lines either had signi®cantly reduced levels or no detectable activity by either HA-substrate gel zymography or by the microtiter-based enzyme assay (Figure 2) . In contrast to the SCC-10a line, the SCC-10b line, which is derived from a lymph node metastasis from the same patient at a later point in disease, had no detectable activity in either assay. The microtiter-based assay is suciently sensitive to detect 1/100th the activity found in the SCC-10a line without immunoprecipitation. Substrate-gel zymography of the cell layer immunoprecipitates from NHK cells and the SCC-10a line possessed an additional *45 kDa lower molecular weight isoform of Hyal-1, similar to a proteolytically processed form of Hyal-1 found in human urine (CsoÂ ka et al., 1997b) . As no hyaluronidase activity could be found in the 17E9-supernates, changes in the 17E9 reactive epitope on Hyal-1 in the de®cient cell lines appeared unlikely.
Immunoblotting of the 17E9-immunoprecipitates from conditioned media and cell layers with polyclonal antibodies against Hyal-1 were also examined ( Figure   Figure 1 HA-substrate gel zymograms of HYAL1 in HNSCC lines and normal keratinocyte controls. 17E9 mAb immunoprecipitates from (a), 1 mg cellular protein and (b), the corresponding conditioned media were examined. Two enzymatic clearings at 57 kDa and 45 kDa were found in the cell layer, whereas only the 57 kDa species (similar to recombinant HYAL1) was found in the conditioned media Figure 2 Microtiter-based assay of enzyme activity in 17E9 immunoprecipitates from cell layer or serum free conditioned media. 17E9 immunoprecipitates in cell layer, conditioned media or cell layer supernates were examined. Activity is expressed as rTRUs. Samples were assayed in triplicate 3). Hyal-1 protein levels were in agreement with the enzyme assays. Hyal-1 protein was only observed in the SCC-10a line and in the NHK cells. These results made post-translational inactivation or the presence of an inhibitor unlikely to account for the absence of enzymatic activity in the cell lines.
RT ± PCR analysis reveals discrepancies between HYAL1 mRNA and protein Reverse transcriptase ± PCR (RT ± PCR) analysis reveals discrepancies between HYAL1 mRNA and protein Reverse transcriptase-PCR (RT ± PCR) analysis of HYAL1 using primers from 482 ± 2278 bp showed that all cells, with the exception of the HOC-313 lymph node metastasis derived cell line, produced mRNA transcripts for HYAL1. The HOC-313 line showed no detectable mRNA with 40 cycles of RT ± PCR, but extended cycles did reveal a weak transcript that was of the correct size. Levels of b-actin from all cell-lines showed no appreciable dierences within the cDNA preparations.
Comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH) analysis of HNSCC cell lines
The apparent discrepancies between Hyal-1 protein levels and HYAL1 mRNA transcripts led to an examination of the HYAL1 gene on chromosome 3p21.3 in these HNSCC lines. We assessed the status of the HYAL1 gene by FISH using a 100 kb genomic PAC probe and compared this to the entire chromosome 3 by CGH. Representative FISH images from each cell line (200 nuclei scored) and CGH revealed a loss of 3p21 and one copy of HYAL1 in the SCC-9, SCC-10a, SCC-15, SCC-25, SCC-10b and HSC-3 relative to the chromosome 3 centromeric probe ( Figure 4 ). The HNSCC lines were generally tetraploid with respect to the centromeric chromosome 3 probe and several other centromeric chromosome markers, but showed varying losses of 3p21.3 from ratios of 3/2 to 4/1 (chromosome-3/.3p21.3). Surprisingly, the HOC-313 cell line possessed equal ratios of centromeric 3p to HYAL1 by both FISH and CGH analysis. The HOC-313 line was diploid in DNA content. This was the only cell line that did not have mRNA, protein, nor activity for Hyal-1. The SCC-10a line on the other hand, expressed HYAL1 mRNA, protein and abundant enzyme activity (*800610
73 TRU/mg/cellular protein), but had a clear loss of one HYAL1 allele by FISH and CGH. This appeared to exclude hemizygosity at 3p21.3 as an adequate explanation for the absence of Hyal-1 activity in these cell lines, and would rule out imprinting of the HYAL1 gene on 3p21.3
The HSC-3 HNSCC line is capable of synthesizing functional HYAL1 under an inducible promoter Given the discrepancies between HYAL1 mRNA levels and protein, we wished to investigate whether the HNSCC lines had the capacity to produce functional Hyal-1 under an inducible promoter. We therefore subcloned the HYAL1 open reading frame into an ecdysone-inducible vector (HYAL1 pIND, Invitrogen) and cotransfected it with the pVgRXR vector into the HSC-3 HNSCC line. As shown in Figure 5 , one of the HSC-3 subclones examined was fully capable of expressing Hyal-1 activity and protein in an inducible fashion in response to increasing concentrations of muristerone (Figure 5b and a, respectively) . The majority of the activity and protein was recovered in the conditioned media. As the HSC-3 line showed no chromosomal aberrations surrounding the HYAL1 gene and produced endogenous transcript for HYAL1 without Hyal-1 protein or enzyme activity, we postulated that mutations could be responsible for the loss of immunoreactive protein.
Sequencing of the full-length cDNA fails to identify mutations in the open reading frame
In light of the apparent discrepancy between mRNA levels and protein, we sequenced the HYAL1 RT ± PCR products from NHKs, SCC-9, SCC-10a, SCC-15, SCC-25, SCC-10b and HSC-3 from bp 482 ± 2278. Sequencing of these RT ± PCR products failed to produce any mutations or polymorphisms that could explain our ®ndings. RT ± PCR analysis of the 5' untranslated region of HYAL1 reveals a novel spliced form that correlates with enzyme and protein levels
We noted that the 5' UTR of HYAL1 was unusually long (611 bp). In addition, the 5' UTR contained eight methionine residues, placing the assumed HYAL1 open reading frame in poor context for expression assuming the ATG at 611 bp as the initiation codon. An expressed sequence tag (EST) for HYAL1 from neuroepithelial cells (AA223264) was found in the EST database (dbEST) that skipped nucleotides 103 ± 585, suggesting that this portion of the 5' UTR might contain a retained intron (Kozak, 1996) . A retained intron can severely limit translation by preventing the ribosome from binding to the correct initiating methionine codon (Kozak, 1991) . The previous primers used would not have ampli®ed such a spliced form, as the forward primer was within this potential ®rst intron. Primers¯anking this potential retained intron were therefore designed that ampli®ed the HYAL1 5' UTR from 15 ± 606 bp. RT ± PCR based analysis identi®ed a shortened 109 bp 5' UTR in the NHK cells and in the SCC-10a line, in addition to the expected 591 bp product (Figure 6b) . Sequencing of the two PCR products from the NHK 5' UTR demonstrated that the splicing occurred between nucleotides (103) to (585) GenBank Accession No. AF118821. This spliced form of HYAL1 correlated very well with the protein and enzyme activity levels demonstrated in Figures 1 and 3 . There was a mixture of the two 5' UTRs in normal keratinocytes and the SCC-10a line, whereas all other cell lines except the HOC-313 ampli®ed predominantly the 591 bp 5' UTR. This 591 bp unspliced 5' UTR form of HYAL1 from Figure 6 was unlikely to be an artifact of genomic DNA contamination, as RT ± PCR using the primers from Intron-1 to Exon-4 produced the predicted 1796 bp product (Figure 6c ) that had retained Intron-1 but spliced out Intron-2 and Intron-3 as determined by sequencing.
Northern blots from normal human tissues also identi®ed 1.9 and 2.5 kb transcripts that correlated with the spiced and unspliced 5' untranslated region of HYAL1 (Figure 7) . We therefore concluded that both of these two forms occur naturally in vivo but that only the spliced form produces the functional enzyme protein that we detected in our assays.
Sequencing of HYAL1 genomic DNA fails to demonstrate mutations in introns or exons
The HYAL1 gene was then ampli®ed from genomic DNA preparations. Sequencing of this full-length genomic DNA from all eight cell lines failed to identify any mutations within the intron/exon splice junctions that could explain the failure of the majority of HNSCC lines to splice out the retained intron within the 5' UTR. The HOC-313 line, which contained neither transcript by RT ± PCR analysis, also lacked any detectable mutations.
Summary of HYAL1 in HNSCC cell lines
A summary of the analysis of HYAL1 in HNSCC is given in Table 1 . Only NHK cells and the SCC-10a line produced comparable levels of enzyme activity, protein, and the spliced form of HYAL1 transcript. The SCC-9, SCC-15, SCC-25, SCC-10b, and HSC-3 lines showed very weak or absent levels of the spliced form of HYAL1, in agreement with the level of enzyme activity found in these cells. Levels of the unspliced form were proportional to that found in the cells producing functional protein. The HOC-313 lines, however, produced neither transcript at levels detectable under the number of cycles examined.
Discussion
The existence of acquired, somatic homozygous deletions over 3p21.3 in human malignancies is suggestive of a tumor suppressor gene locus. The presence of a functional tumor suppressor activity encompassing this region (Cheng et al., 1998) supports such a hypothesis. Homozygous deletions have been described in this region both in vitro and in vivo (Todd et al., 1997) , but no mutations of any of the genes in this deleted region have been reported with high frequency in carcinomas in (Haber and Harlow, 1997; Sager, 1997) . Although the HYAL1 gene product is not produced in the majority of HNSCC lines examined, the mechanism appears to be independent of the loss of heterozygosity. Several factors have made re®ning the candidate TSG locus on 3p21.3 dicult. First, the high gene density of 3p21.3 makes it dicult to identify a particular gene, even with a 30 kb homozygous deletion. Second, many genes on chromosome 3p21 are silenced at least in small cell lung carcinoma by some unknown mechanism (Scaloni et al., 1992) . Finally, chromosome 3p is postulated to harbor other tumor suppressor gene loci, such as at the 3p14-p12 Fragile Histidine Triad (FHIT) region (Druck et al., 1998) and at 3p25, the von Hippel-Lindau (VHL) disease region (Hibi et al., 1992) , making the larger chromosomal deletions dicult to interpret.
The lack of a functional HYAL1 gene product in the majority of examined HNSCC lines is still intriguing, given that this gene resides within a potentially informative 30 kb homozygous deletion. Although large chromosomal aberrations over 3p were found in the HNSCC lines, hemizygosity did not necessarily correlate with the loss of enzyme activity or protein. The SCC-10a line produced enzyme activity and properly spliced the 5' UTR. However, this cell line showed clear deletions of the 3p21.3 locus by FISH and CGH analysis. This demonstrated that one copy of the HYAL1 gene is sucient to generate normal levels of enzyme activity.
The SCC-9, SCC-15, SCC-25, SCC-10b and HSC-3 lines expressed predominantly mRNA transcripts retaining the 5' UTR intron. This unspliced 5' UTR leaves the transcript in poor context for expression. A mixture of the spliced and unspliced 5' UTR were found in NHK cells and in human tissues by Northern blot, demonstrating that this unspliced form is a more general phenomenon and not exclusive to malignancies. Few examples of post-transcriptional regulation such as this exist in eukaryotic biology. The sex-lethal autoregulatory circuit in drosophila is one such model where 5' UTR splice variants regulate gene expression (Granadino et al., 1997) . Aberrant or alternative splicing of other candidate tumor suppressor genes such as FHIT and TSG101 have been reported, and generally appear to be epigenetic rather than mutations at intron-exon boundaries (Gayther et al., 1997) .
The spliced 109 bp 5' UTR product was present at very low levels after 40 cycles of PCR in some of the carcinoma lines. These results are in agreement with the 17E9 enzyme assays that detected HYAL1 at levels several log fold lower than the NHK or SCC-10a lines (0.5 ± 25 TRU610
73 versus 500 ± 800 TRU610
73
/mg cellular protein, respectively). The reason for this basal level of HYAL1 gene expression is unclear. This residual activity could result from the heterogeneous nature of the tumor cell populations. The FISH analysis supports the idea of 3p21.3 heterogeneity in copy number ratios of 3p21.3/Cen-3 per cell. Alternatively, incomplete epigenetic silencing of the splicing machinery is equally plausible.
In contrast to these splicing aberrations, the HOC-313 line lacked both transcripts for HYAL1 and yet was normal by both CGH and FISH. Preliminary studies showed a dose dependent reactivation of Hyal-1 enzyme activity in this cell line following a 72 h treatment with 5-aza-2'-deoxycytidine (data not shown). This raises the possibility that the HYAL1 gene is hypermethylated in the HOC-313 line. However, this has not been veri®ed by sequencing metabisul®te-treated DNA to con®rm that the CpGisland immediately upstream of HYAL1 is eected.
We have not examined the status of other hyaluronidase activities or their genes such as HYAL2, immediately adjacent to HYAL1 on 3p21.3 (CsoÂ ka et al., 1999). Our hyaluronidase activity assays have been unable to detect recombinant Hyal-2 enzymatic activity using either the microtiter-based or HA substrate gel assays. The covalently bound biotinylated HA may not serve as an available substrate. Nevertheless, all enzyme activity as measured in both assays could be immunoprecipitated with the 17E9 mAB. There did not appear to be a cofactor required for enzyme activity, as the HSC-3 line was capable of producing Hyal-1 protein and activity when the HYAL1 gene was introduced without the 5' UTR region. These studies point towards the 5' UTR as the rate-limiting step in the production of enzyme activity.
The presence of nine start codons in the retained intron 1, and a number of stop codons, three of which are in frame with start codons, provide a mechanism for the failure of some cell lines to translate HYAL1 (Kozack, 1996; Zhang et al., 1998) . The presence of aberrant splicing may be more ubiquitous than previously assumed (Maquat, 1996) . Such retained introns, and¯awed pre-mRNAs are suggested to have modulating functions, and are present in apparently normal tissues, as shown in the Northern analysis of human tissues (Figure 7 ).
It appears that in the HNSCC lines, either aberrant splicing or possibly hypermethylation silences the HYAL1 gene. The HYAL1 gene was inactivated or suppressed in six of the seven cell lines examined, but inactivating mutations were not shown to be the cause. Both hypermethylation and the aberrant splicing could be explained as mere bystander eects. Without evidence for a functional role of HYAL1 in suppressing tumorigenicity, these ®ndings are simply associative in nature. In conclusion, although the HYAL1 gene is inactivated in HNSCC lines, the mechanisms responsible for such inactivation do not appear to be directly associated with the chromosomal aberrations at 3p. However, further investigations of this candidate tumor suppressor gene, along with the other candidate genes in this region, are warranted.
Materials and methods
Cell culture SCC-9, SCC-15, SCC-25 squamous cell carcinoma lines were from the ATCC. SCC-10a, SCC-10b, HSC-3 and HOC-313 cell lines were kindly provided by RH Kramer (Oral Cancer Research Center, UCSF) . The NHK cell cultures (normal human foreskin keratinocytes) were obtained from Clonetics (San Diego, CA, USA) or were generated as described previously . The NHK cells were routinely cultured in serum-free de®ned keratinocyte basil media (KBM, Life Technologies, Gaithersburg, MD, USA) with antibiotics except for experiments for comparison of SCC lines. SCC lines were cultured in DME H21/F12 50 : 50 mix with 10% FBS plus antibiotics. For the analysis of serum-free cultures, all cells were grown in DME H21/F12 50 : 50 mix plus antibiotics with insulin, transferrin and selenium.
Analysis of HYAL1 hyaluronidase activity in HNSCC cell lines
Hyaluronidase activity was measured using the microtiterbased assay as described , with biotinylated human umbilical cord HA as substrate (ICN, Costa Mesa, CA, USA). The HA substrate gel zymography procedure was performed as previously described (Guntenhoener et al., 1992) using 100 mg/ml HA, ®nal concentration. HNSCC lines or normal NHK cells were seeded at 2610 6 cells in the presence of serum or KBM respectively, and were cultured overnight. Cells were washed 65 with serum-free media and were then incubated for 48 h. Cell layers were harvested with 3 ml/T75 with PBS+60 mM octylglucoside (Boehringer-Mannheim, Indianapolis, IN, USA) and protease inhibitors (Complete Boehringer-Mannheim) plus 100 U/ml DNAase (Boehringer-Mannheim) and extracted for 1 h on ice. Octylglucoside and protease inhibitors were also added to conditioned media samples. Samples were then immunoprecipitated with 17E9 IgG2a anti-hyaluronidase antibodies conjugated to protein-A beads (1.5 mg IgG2a/mg cellular protein) and were incubated overnight at 48C. Beads were collected by centrifugation and washed once with PBS. Immunoprecipitates were then measured for enzyme activity by HA substrate gel zymography or by the microtiter-based assay. For zymography, immunoprecipitates were incubated with 5% SDS without reducing agents at room temperature. Beads were pelleted by centrifugation and supernatants electrophoresed on 10% SDS gels impregnated with 100 mg/ ml HA (ICN). Gels were then incubated with 3% Triton X-100 followed by incubation overnight in formate buer pH 3.7 with 0.15 M NaCl. Enzyme degradation was then detected with Alcian blue staining followed by Coomassie blue R250 counterstaining. For the microtiter-based assay, immunoprecipitates were brought up into 0.1 M formate pH 3.7 with 0.1 M NaCl and 3% Triton X-100 and incubated in the microtiter based assay for 45 min. Enzyme activity was described as relative turbidity-reducing units (rTRU) based upon a standard curve of calibrated commercial enzyme.
Western blot analysis of HYAL1
Immunoprecipitates of HYAL1 using the 17E9 monoclonal antibodies from 1 mg of total cellular protein or equivalent conditioned media were electrophoresed on 12% gels and blotted to PVDF membranes. Membranes were blocked with 5% milk block followed by probing with rabbit polyclonal antibodies diluted 1 : 2000 raised against immunoanitypuri®ed recombinant enzyme from HEK cells overexpressing HYAL1 and detected with ECL (Amersham, Arlington Heights, IL, USA).
RT ± PCR analysis of HYAL1 Cytoplasmic RNA was isolated from normal keratinocytes and HNSCC lines by NP-40 lysis and was puri®ed with the Qiagen RNA isolation kit. RNA was reverse transcribed using the Thermoscriptase kit (Life Technologies) and 3 mg of total RNA per cell line. For ampli®cation of the HYAL1 open reading frame from (482 to 2278 bp), RT ± PCR was performed using Expand 1 . High Fidelity polymerase mix (Boehringer-Mannheim) for 40 cycles using HYAL1F1 (CAGAGCAGCGGTG-GATTAATGCG) and HYAL1R1 (AAGTCCACATAAAAC-GCTTAGCACGG) with a 958C denaturing step for 3 min followed by 958C 30 s, 628C 30 s, 728C for 2 min plus an additional 5 s/cycle from cycles 10 ± 30 and a ®nal extension of 10 min at 728C. Control b-actin primers were bAF (AACACC-CCAGCCATGTACGTTGC) and bAR (TCCTTCTGCATC-CTGTCGGCAA) and run under the same conditions as HYAL1F1 and HYAL1R1. For examination of the HYAL1 5' untranslated region from (15 to 606 bp) primers used were HYAL1F2 (GCAGCTGGGGTGGAATCTGGC) and HYAL1R2 (CGGGACTGGTCGAGGACAACCT) with a 958C denaturing step for 3 min followed by 958C 30 s, 638C 30 s, 728C for 1 min plus an additional 5 s/cycle from cycles 10 ± 30, and a ®nal extension of 10 min at 728C. For ampli®cation of the genomic HYAL1 sequence from (7104 to 2278 bp), primers HY1F3 (CTGGCCTGGCCTCCTA-ATCCAAG) and HYAL1R1 were used with a 958C denaturing step for 3 min followed by 958C 30 s, 628C 30 s, 728C for 2 min plus an additional 5 s/cycle from cycles 10 ± 30 and a ®nal extension of 10 min at 728C. For sequencing PCR products, bands were excised and eluted with the Gel Extraction Kit (Boehringer-Mannheim). All sequencing reactions were performed on double-stranded DNA with the Taq dye deoxy terminator cycle sequencing kit (Applied Biosystems) according to the manufacturer's instructions, and run on an ABI Prism TM automated sequencer (Applied Biosystems, Foster City, CA, USA).
Generation of an ecdysone-inducible HYAL1 construct in the HSC-3 cell line
The HYAL1 construct used previously for expression was subcloned from the PCR3.1-Uni vector into the Ecdysone-responsive pIND vector (Invitrogen, San Diego, CA, USA). The HYAL1 pIND vector was cotransfected into the HSC-3 line with the pVgRXR vector using lipofectin (Life Technologies). Cells were selected in 500 mg/ ml G418/500 mg/ml Zeocin and cloned by limiting dilution. Clones overexpressing HYAL1 were screened using the microtiter-based assay in the absence and presence of muristerone-A. A dose response of muristerone (0 ± 10 mM) was used to examine the range of inducible HYAL1 activity. HYAL1 protein levels were determined by immunoprecipitation and Western blot analysis as described above.
Fluorescence in situ hybridization analysis of HYAL1 in HNSCC cell lines A PAC probe spanning HYAL1 on 3p21.3 (CsoÂ ka et al., 1998) was biotinylated with dATP using the BRL BioNick labeling kit (Life Technologies) and used for FISH analysis of normal keratinocytes and HNSCC lines as described (Mohapatra et al., 1997) . Two hundred nuclei were scored for each cell line as a ratio of chromosome 3-centromeric probe to the HYAL1 PAC signal.
Comparative genomic hybridization of HNSCC cell lines
Comparative genomic hybridization of HNSCC lines and normal keratinocytes was performed as described previously (Mohapatra et al., 1995) .
Northern blot analysis of HYAL1 mRNA forms in human tissues
A human multiple tissue poly(A) + Northern blot (Clontech) was probed using a 32 P random primed HYAL1 cDNA that was excised and gel-puri®ed from a PCR 31.-UNI vector. Blots were exposed for 19 h.
